Avoca Quality Consortium Announces 2013 Key Initiatives

  Avoca Quality Consortium Announces 2013 Key Initiatives

    Eli Lilly & Co. and Pfizer, Inc. continue as lead Consortium sponsors

Business Wire

PRINCETON, N.J. -- January 24, 2013

The Avoca Group, an industry-leading consulting and research organization
specializing in clinical outsourcing and alliance management, announced today
the Avoca Quality Consortium’s 2013 key initiatives. Building upon a
successful launch year, the Avoca Quality Consortium will implement additional
initiatives aimed at further enabling members to optimize approaches for
proactive quality management of outsourced clinical trials.

Formed in January of 2012 with 29 members, The Avoca Quality Consortium brings
together executives from pharma, biotech, and clinical research organizations
(CROs) to accelerate the development of best practice approaches to quality
management. Over the past year, the Consortium successfully completed the
creation of a Clinical Quality Agreement template and a Quality Metrics

“Our overarching goal is to help our diverse members strike the right balance
between meeting timelines, ensuring cost containment and achieving the highest
level of quality in their clinical trials,” explained Patricia Leuchten,
President and CEO of Avoca. “We made tremendous progress during our first year
and are now poised to expand the scope of this critically important work.”

For 2013, the Quality Consortium will conduct a consortium-wide research
assessment focused on managing risk in outsourced clinical trials. This will
include an assessment of Consortium members’ approaches to managing risk
compared to the overall industry’s approach.

“At a time of increasing regulatory expectations, industry collaboration to
raise the bar on quality in critical trials is more important than ever,” said
Jeff Kasher, Ph.D., Vice President, Clinical Trial: Materials, Implementation,
and Transformation, Eli Lilly Co. “Our first year work produced very practical
tools, which many members have already put into use. Our 2013 focus on
guidelines and tools for effective oversight will continue in the same spirit:
research that leads to useable tools to support proactive quality management.”

Research and work on leading practices in proactive quality management serve
as the two pillars of the Avoca Quality Consortium. Members of the Avoca
Quality Consortium will receive 2013 guidelines and tools focused on effective
oversight, revisions and refinements to its quality agreement and metrics
tools, Avoca research reports, participation in the May Summit and Fall
Working Sessions, participation in regular WebEx Meetings and updates on work
related to avenues for operationalizing approaches to proactive quality

Eli Lilly & Company and Pfizer, Inc. are founding corporate sponsors and will
continue in that role during 2013. Jeff Kasher and John Hubbard, Ph.D., FCP,
Senior Vice President and Worldwide Head Development Operations, Pfizer, Inc.
will co-chair the Consortium’s Annual Summit set for May 8&9 in Princeton, NJ.

For more information about the Avoca Quality Consortium, or to inquire about
membership, please contact caryn.laermer@theavocagroup.com at (609) 799-0511,
or visit the The Avoca Quality Consortium.


Social Surge Interactive
Brittany Hutt, 610-212-1230
General Information:
The Avoca Group
Caryn Laermer, 609-799-0511
Senior Manager, Quality Consortium
Press spacebar to pause and continue. Press esc to stop.